Director Curtis Rosebraugh Resigns from Ensysce Biosciences Board
ENSC sits 83% above its 52-week low of $0.314.
Summary
Ensysce Biosciences reported the resignation of Director Curtis Rosebraugh, who confirmed his departure was not due to any disagreements with the company.
Key Events · Executive and Board Changes · ENSC
-
Director Resignation
Curtis Rosebraugh resigned from the Board of Directors of Ensysce Biosciences, Inc., effective April 1, 2026.
-
Committee Membership
Dr. Rosebraugh was a member of the Nominating and Corporate Governance Committee prior to his resignation.
-
No Disagreement Stated
The resignation notice explicitly states that the departure was not a result of any disagreement with the Company, its management, or the Board.
Analysis · ENSC · Life Sciences
Ensysce Biosciences announced the resignation of Director Curtis Rosebraugh, effective April 1, 2026. Dr. Rosebraugh, who served on the Nominating and Corporate Governance Committee, explicitly stated his departure was not due to any disagreements with the company or its board. This follows a recent director resignation on March 27, 2026, which *was* attributed to fundamental disagreements. While this current resignation is amicable, it marks another change in the company's board composition in a short period, indicating ongoing shifts in governance.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $0.31 to $4.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.